Trial Profile
Phase II Study of the Combination of Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma A University of California Hematologic Malignancies Consortium Protocol (UCHMC1809)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 12 Jan 2024
Price :
$35
*
At a glance
- Drugs Daratumumab (Primary) ; Daratumumab (Primary) ; Dexamethasone (Primary) ; Ixazomib (Primary) ; Pomalidomide (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- Acronyms UCHMC1809
- 08 Jan 2024 Planned primary completion date changed from 1 Oct 2023 to 1 Mar 2024.
- 12 Dec 2023 Results reporting safety and efficacy data of addition of Ixazomib to DPd (DIPd) in patients with early RRMM presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 27 Mar 2023 Planned End Date changed from 1 Oct 2022 to 1 Oct 2024.